The founder, MD, and CEO of Foresite Capital is Jim Tananbaum. The guy has over 25 years’ experience in building and investing in health care ventures. Jim uses strategic, operational, and financial tactics to build successful healthcare businesses.
Earlier in his life, he was a partner at Prospect Venture Partner II and III and Sierra Ventures – companies he helped establish their healthcare investment side. Some of his investments are Jazz Pharmaceuticals, Amira Pharmaceuticals, Amerigroup, and Healtheon.
Before Foresite Capital, Jim has held leading positions at GelTex Pharmaceuticals and Theravance Inc. GelTex was able to introduce two drugs to the market for less than $80 million. Today, these drugs are generating more than $1 billion in revenue. GelTex was acquired for $1.6 billion.
Jim Tananbaum went to Yale University and graduated with a BS and B.S.E.E. He also holds an MD from Harvard Medical School and an MIT & MBA from Harvard Business School. He then got an opportunity to serve on the advisory boards to the Harvard-MIT HST program and Yale University (school of engineering.
Jim Tananbaum was ranked #52 on the Forbes Midas List of “Top Tech Investors” for three years in a row. The list recognizes the best 100 venture capitalists that make smart investments in the leading tech companies and create value for their investors. The initiative is a partnership between Forbes and TrueBridge Capital. They collect data from public resources, historical lists and direct submissions from venture capital enterprises.
About Foresite Capital
Foresite Capital is a venture capital in the healthcare space, founded in 2011. It specializes in providing support and the much-needed capital to companies with exceptional services and products in healthcare.
The company collaborates with visionary and innovative entrepreneurs to bring value and improve the quality of health care services. The firm recently named Molly He, Ph.D. a venture partner.